Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773777 | 0.91 | NAMPT (0.43) | CCR1P2RY12CNR1NAMPT | |
| SCHEMBL2776029 | 0.90 | CNR1 (0.40) | CCR1P2RY12CNR1P2RX7 | |
| SCHEMBL2775592 | 0.89 | HRH3 (0.42) | P2RY12CNR1P2RX7NAMPTHRH1 | |
| SCHEMBL2774490 | 0.89 | CCR1 (0.52) | CCR1P2RY12CNR1NAMPT | |
| SCHEMBL12977930 | 0.88 | NAMPT (0.43) | CCR1P2RY12NAMPT | |
| SCHEMBL2776300 | 0.87 | CCR1 (0.46) | CCR1P2RY12CNR1NAMPTHRH1 | |
| SCHEMBL2776115 | 0.87 | CNR1 (0.41) | CCR1P2RY12CNR1P2RX7NAMPT | |
| SCHEMBL2777374 | 0.87 | LMNA (0.44) | CCR1P2RY12P2RX7 | |
| SCHEMBL2774059 | 0.87 | P2RY12 (0.45) | CCR1P2RY12CNR1NAMPT | |
| SCHEMBL2775315 | 0.87 | CCR1 (0.42) | CCR1P2RY12CNR1P2RX7NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | claimed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | claimed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | CCR1 1428/4885P2RY12 2053/4885CNR1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.